{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-111979","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.390693+00:00","generated_at":"2026-05-16T19:49:47.352396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fortress Biotech Q3 net revenue up 20.5% to $17.6M; net income $3.7M vs prior loss","bullets":["Net revenue $17.6M (Q3 2025) vs $14.6M (Q3 2024), driven by dermatology product sales.","Net income attributable to common stockholders $3.7M ($0.13 basic EPS) vs net loss of $15.0M in Q3 2024.","Cash and equivalents $86.2M as of Sep 30, 2025, up from $57.3M at Dec 31, 2024.","Checkpoint sale to Sun Pharma closed May 2025; Fortress received ~$28M upfront plus up to $4.8M CVR and 2.5% royalty on UNLOXCYT sales.","Dotinurad Phase 3 trials dosed Oct 2025; Crystalys raised $205M Series A; Urica (Fortress sub) holds equity and 3% royalty."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-111979","json":"https://secwatch.observer/filing/0001104659-25-111979.json","markdown":"https://secwatch.observer/filing/0001104659-25-111979.md","text":"https://secwatch.observer/filing/0001104659-25-111979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/0001104659-25-111979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:49:47.352396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}